Shukra Pharmaceuticals Intrinsic Value
Shukra Pharmaceuticals intrinsic value. Shukra Pharmaceuticals (SHUKRAPHAR) median intrinsic value is ₹32.88 from 10 valuation models (range ₹25–₹164), vs current price ₹82.20 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse Shukra Pharmaceuticals shareholding analysis to track promoter, FII and institutional holdings.
SHUKRAPHAR Valuation Methods Summary — DCF, Graham Number & P/E
Shukra Pharmaceuticals intrinsic value across 10 models vs current price ₹82.20 — upside/downside and value range per method. Browse Shukra Pharmaceuticals annual reports for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹25.52 | ₹20.42 - ₹30.62 | -69.0% | EPS: ₹1.16, Sector P/E: 22x |
| Book Value Method | asset | ₹40.91 | ₹36.82 - ₹45.00 | -50.2% | Book Value/Share: ₹20.45, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹81.82 | ₹73.64 - ₹90.00 | -0.5% | Revenue/Share: ₹40.91, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹164.40 | ₹147.96 - ₹180.84 | +100.0% | EBITDA: ₹76.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹32.88 | ₹26.30 - ₹39.46 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹24.66 | ₹22.19 - ₹27.13 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹24.66 | ₹22.19 - ₹27.13 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹164.40 | ₹147.96 - ₹180.84 | +100.0% | ROE: 57.8%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹24.66 | ₹22.19 - ₹27.13 | -70.0% | EPS: ₹1.16, BVPS: ₹20.45 |
| Dividend Yield Method | dividend | ₹24.66 | ₹22.19 - ₹27.13 | -70.0% | DPS: ₹0.01, Target Yield: 2.5% |
SHUKRAPHAR Intrinsic Value vs Market Price — All Valuation Models
Shukra Pharmaceuticals fair value range ₹25–₹164 vs current market price ₹82.20 across 10 valuation models. For current market price and key ratios, visit Shukra Pharmaceuticals share price screener.
SHUKRAPHAR Intrinsic Value Analysis — Undervalued or Overvalued?
Shukra Pharmaceuticals median intrinsic value ₹32.88, current price ₹82.20 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.
What is the intrinsic value of SHUKRAPHAR?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Shukra Pharmaceuticals (SHUKRAPHAR) is ₹32.88 (median value). With the current market price of ₹82.20, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹24.66 to ₹164.40, indicating ₹24.66 - ₹164.40.
Is SHUKRAPHAR undervalued or overvalued?
Based on our multi-method analysis, Shukra Pharmaceuticals (SHUKRAPHAR) appears to be trading above calculated value by approximately 60.0%.
SHUKRAPHAR Financial Health — Key Ratios vs Industry Benchmarks
Shukra Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 57.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 42.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.54x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
SHUKRAPHAR Cash Flow Quality — Operating & Free Cash Flow
Shukra Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹3 Cr | ₹-4 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹8 Cr | ₹8 Cr | Positive Free Cash Flow | 8/10 |